Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3787712
Max Phase: Preclinical
Molecular Formula: C85H132N26O17
Molecular Weight: 1790.16
Molecule Type: Small molecule
Associated Items:
ID: ALA3787712
Max Phase: Preclinical
Molecular Formula: C85H132N26O17
Molecular Weight: 1790.16
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CCCCCCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN/C(N)=N/C(=O)NCCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Standard InChI: InChI=1S/C85H132N26O17/c1-49(2)43-65(77(124)103-59(15-11-39-96-81(89)90)73(120)107-63(71(87)118)45-51-21-29-55(112)30-22-51)109-75(122)61(17-13-41-98-83(93)94)105-79(126)67(47-53-25-33-57(114)34-26-53)101-69(116)19-7-5-6-8-20-70(117)102-68(48-54-27-35-58(115)36-28-54)80(127)106-62(18-14-42-99-84(95)111-85(128)100-38-10-9-37-86)76(123)110-66(44-50(3)4)78(125)104-60(16-12-40-97-82(91)92)74(121)108-64(72(88)119)46-52-23-31-56(113)32-24-52/h21-36,49-50,59-68,112-115H,5-20,37-48,86H2,1-4H3,(H2,87,118)(H2,88,119)(H,101,116)(H,102,117)(H,103,124)(H,104,125)(H,105,126)(H,106,127)(H,107,120)(H,108,121)(H,109,122)(H,110,123)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)(H4,95,99,100,111,128)/t59-,60-,61-,62-,63-,64-,65-,66-,67-,68-/m0/s1
Standard InChI Key: NIPARCYTBXBSLE-WVRXEKPCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1790.16 | Molecular Weight (Monoisotopic): 1789.0264 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kuhn KK, Ertl T, Dukorn S, Keller M, Bernhardt G, Reiser O, Buschauer A.. (2016) High Affinity Agonists of the Neuropeptide Y (NPY) Y4 Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling., 59 (13): [PMID:27223253] [10.1021/acs.jmedchem.6b00309] |
Source(1):